Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics

Poseida Therapeutics Inc. (PSTX): $7.95

0.28 (+3.65%)

POWR Rating

Component Grades













PSTX Stock Price Chart Interactive Chart >

Price chart for PSTX

PSTX Price/Volume Stats

Current price $7.95 52-week high $13.98
Prev. close $7.67 52-week low $7.53
Day low $7.62 Volume 134,169
Day high $7.98 Avg. volume 266,986
50-day MA $8.63 Dividend yield N/A
200-day MA $9.25 Market Cap 495.60M

Poseida Therapeutics Inc. (PSTX) Company Bio

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.

PSTX Latest News Stream

Event/Time News Detail
Loading, please wait...

PSTX Latest Social Stream

Loading social stream, please wait...

View Full PSTX Social Stream

Latest PSTX News From Around the Web

Below are the latest news stories about Poseida Therapeutics Inc that investors may wish to consider to help them evaluate PSTX as an investment opportunity.

Chief Executive Officer Of Poseida Therapeutics Trades $335.44 Thousand In Company Stock

Eric Ostertag, Chief Executive Officer at Poseida Therapeutics (NASDAQ:PSTX), made a large buy and sell of company shares on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 14, Eric Ostertag bought 21,281 Poseida Therapeutics shares at prices ranging from $1.17 to $9.15 per share, for a total of $172,729. They then sold their shares on the same day in the open market at a price of $8.14 to rais

Yahoo | September 16, 2021

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:

Yahoo | September 7, 2021

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Every investor in Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) should be aware of the most powerful shareholder groups...

Yahoo | September 2, 2021

Poseida''s Solid Tumor CAR-T Candidate Data Fails To Impress Investors

The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX ) hard last August, but since

Business Insider Markets | August 31, 2021

Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors

The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy. The Company announced interim results for P-PSMA-101, solid tumor autologous CAR-T product candidate for metastatic castrate-resistant prostate cancer (mCRPC). The Company was bullish on the presentation today, but investors apparently were not impressed. The caveat is that it is Phase

Yahoo | August 31, 2021

Read More 'PSTX' Stories Here

PSTX Price Returns

1-mo -8.62%
3-mo -20.66%
6-mo -13.40%
1-year -16.32%
3-year N/A
5-year N/A
YTD -27.53%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7317 seconds.